Feasibility and preliminary biomarker responses to capsules containing green coffee extract enriched with magnesium di-malate in women with type 2 diabetes mellitus: a randomized, placebo-controlled p
Authors: Moura de Araújo MF, Garcia Lira Neto JC, Lima Inácio FS, Freitas Costa TS, Júnior Freire de Freitas RW, Coelho Damasceno MM, do Livramento de Paula M, Costa Pereira LF, Pinheiro Landim Almeida CA, de Souza Teixeira CR
Journal: Revista peruana de medicina experimental y salud publica
mental health
psychology
open access
Abstract
Smoking is a leading modifiable risk factor for cancer-related morbidity and mortality among adults in the United States. Continued smoking among cancer survivors is associated with poorer response to treatment and higher incidence of second primary cancer diagnoses. Tobacco cessation following a cancer diagnosis promotes improved health and longevity. Clinical practice guidelines recommend delivery of smoking cessation treatment as an essential component of cancer care. Evidence-based tobacco cessation interventions for cancer survivors include counseling and use of FDA-approved smoking cessation medications. Existing treatments include brief and extended behavioral counseling, including intensive tobacco cessation counseling adapted for patients with cancer or oncology-clinician delivered 5As (i.e., Ask, Advise, Assess, Assist, Arrange). Despite clear benefits of tobacco cessation treatment for cancer survivors, there have been challenges with systematic integration of tobacco cessation treatment within cancer care settings. Barriers to integration of tobacco cessation treatment in routine oncology care include lack of standardized tobacco assessment procedures or mechanisms for documentation and referral and limited access to tobacco treatment specialists. Accordingly, even less is known about longitudinal patterns of smoking behavior and use of behavioral and pharmacological treatment in clinical trials and routine cancer care. The current study aims to characterize baseline rates of tobacco use, use of cessation support (including oncology clinician intervention), and changes in tobacco use over time among participants enrolled in 9 of 10 ECOG-ACRIN Cancer Research Group trials. This work fills an important gap in the field’s knowledge of prevalence and patterns of smoking and cessation behavior across survivors of a broad range of cancers. The nine trials varied on cancer type and participant gender, yielding a diverse and representative sample of cancer survivors.